For over a decade, Genzyme and our parent company Sanofi have each been working to develop novel treatments for relapsing/remitting MS. We have integrated these two programs within Genzyme to establish ourselves as a leader in MS.
In addition to these late-stage programs we continue to conduct cutting-edge research in MS, focusing on developing medicines to repair the damaged immune system and treat progressive MS.
What is Multiple Sclerosis?
Multiple sclerosis is a chronic disease that affects each person differently, with symptoms ranging from numbness in the limbs or forgetfulness to paralysis or loss of vision. MS is caused when the body’s immune system attacks the central nervous system, damaging the myelin sheath – the protective layer covering the nerves that carry signals between the brain and spinal cord and the rest of the body.
Finding effective treatments for a complex disease like multiple sclerosis is no easy task, but our MS research is spearheaded by top experts employing some of the most advanced and creative scientific problem-solving skills in the industry.
We recognize that truly personalized medicine involves developing relationships with patients and caregivers, health care providers, and disease organizations and foundations.
We have built our MS business unit on the same core principle that has guided our company from the beginning: the importance of deeply understanding the experiences, challenges, and triumphs of those living with a disease. We aim to foster close connections with patients and their families to best understand their needs and to deliver services that have a positive impact.